Catalog No.
Product Name
Application
Product Information
Citations
-
Somatostatin Analog
RC-160 [Lys(Boc)] is an 8-amino acid peptide analog of somatostatin, which primarily acts on somatostatin receptors. It exhibits significant activity in inhibiting hormone secretion and has potential applications in research focused on neuroendocrine regulation and tumor biology. This compound serves as a valuable tool for studying the physiological effects of somatostatin and its analogs in various biological systems. -
Somatostatin Receptor Antagonist
BIM-23056 TFA is a linear octapeptide that serves as a potent antagonist of the somatostatin receptors sst3 and sst5, exhibiting Ki values of 10.8 nM and 5.7 nM, respectively. It effectively inhibits somatostatin-mediated signaling, making it a valuable tool for studying the physiological roles of somatostatin receptors in various biological processes. This compound is suitable for research applications involving endocrine function and neuroendocrine tumor studies. -
Somatostatin Agonist
Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11) is a potent somatostatin agonist that selectively activates somatostatin receptors. It demonstrates significant biological activity in modulating hormone secretion and inhibiting cellular proliferation. This compound is primarily utilized in cancer research, particularly in studies focused on tumor growth regulation and neuroendocrine function. -
SSTR Agonist
BIM-23190 is a somatostatin analog that selectively targets somatostatin receptor subtype 2 (SSTR2) and subtype 5 (SSTR5), exhibiting Ki values of 0.34 nM and 11.1 nM, respectively. This compound acts as an agonist, demonstrating significant biological activity in modulating neuroendocrine functions. BIM-23190 is applicable in research areas related to cancer and acromegaly, making it a valuable tool for studying somatostatin signaling pathways and therapeutic interventions. -
SSTR2 Binder
NOTA-TATE is a selective somatostatin receptor 2 (SSTR2) binder. It specifically targets SSTR2-positive tumor cells, facilitating their visualization through PET imaging. This compound is particularly valuable in the research of neuroendocrine tumors, advancing both diagnostic and therapeutic applications in oncology. -
sst2 Receptor Agonist
Sst2 Receptor Agonist-1 is a highly potent agonist for the somatostatin receptor subtype 2 (sst2), exhibiting a Ki value of 0.025 nM and a cAMP IC50 of 4.8 nM. It effectively inhibits growth hormone (GH) secretion in rats and demonstrates anti-angiogenic properties by preventing ocular neovascular lesion formation. This compound is valuable for research in endocrine regulation and angiogenesis. -
Somatostatin Analogue
Axareotide is a synthetic analogue of somatostatin that acts primarily on somatostatin receptors. It is known for its inhibitory effects on hormone secretion, particularly growth hormone and insulin. Axareotide is utilized in research focused on neuroendocrine tumors, acromegaly, and other conditions associated with abnormal hormone levels, providing valuable insights into somatostatin signaling pathways. -
Somatostatin Analogue
Wy 41747 is a long-acting somatostatin analogue that primarily targets somatostatin receptors. This compound exhibits significant biological activity in modulating hormone secretion and is primarily utilized in research focused on diabetes mellitus and related endocrine disorders. Its prolonged action enables detailed studies of the physiological effects and therapeutic potential of somatostatin analogues in metabolic diseases. -
SST4 Agonist
L803 is a selective agonist of the Somatostatin Receptor Subtype 4 (SST4). It has been shown to inhibit L-type calcium channel currents (ICa). This compound is particularly relevant for research involving retinal ganglion cell (RGC) degenerative diseases, such as glaucoma, facilitating the investigation of therapeutic targets for neuroprotection and preservation of RGC function. -
Somatostatin Receptor Agonist
L-779976 is a somatostatin receptor agonist that exhibits notable anxiolytic effects. When administered into the amygdala and septum of rat brains, it has been shown to modulate anxiety-related behaviors through its complex interactions with somatostatin receptors. This compound is instrumental in research applications focusing on anxiety disorders and neuropharmacology, enabling the investigation of somatostatin's role in stress responses and emotional regulation. -
Somatostatin Receptor Inhibitor
SRA880 free base is a somatostatin receptor inhibitor, specifically targeting the somatostatin-1 autoreceptor. This compound exhibits antidepressant-modulating effects and has been shown to enhance the efficacy of imipramine, resulting in antidepressant-like outcomes. Additionally, SRA880 influences brain-derived neurotrophic factor (BDNF) mRNA expression and modulates the phosphorylation of associated proteins, making it a valuable tool in neurobiological research focusing on mood disorders and related pathways. -
Somatostatin Analog
Ilatreotide is a potent somatostatin analog known for its improved oral bioactivity. It effectively suppresses both fasting and postprandial secretion of various gastrointestinal and pancreatic hormones. This compound is valuable for research into gastroenteropancreatic tumors and offers insights into hormonal regulation in related pathologies. -
Somatostatin Receptor Agonist
SSTR4 Agonist 5 is a potent, orally active agonist of the somatostatin receptor 4 (SSTR4) with an EC50 value of 0.228 nM. Demonstrating considerable stability in human and rat liver microsomes, this compound has shown effectiveness in inhibiting mechanical hyperalgesia in rat models. It is a valuable tool for research applications involving pain mechanisms and SSTR4-related pathways. -
Somatostatin Receptor Agonist
L-054522 is an agonist for somatostatin receptor subtype 2, featuring a Kd of 0.01 nM. This compound effectively inhibits growth hormone secretion from rat primary pituitary cells with an IC50 of 0.05 nM, as well as glucagon and insulin release from isolated mouse pancreatic islet cells, exhibiting IC50 values of 0.05 nM and 12 nM, respectively. L-054522 serves as a valuable tool for exploring somatostatin signaling and its impact on endocrine functions in research applications. -
Somatostatin Analogue
(D-Trp8,D-Cys14)-Somatostatin-14 is a synthetic analogue of somatostatin, targeting somatostatin receptors. This peptide exhibits significant biological activity in modulating hormonal secretion and inhibiting cell proliferation, making it valuable in research related to metabolic disorders and neuroendocrine tumors. Its unique structure allows for enhanced stability and potency in various biological assays. -
Somatostatin Receptor Inhibitor
Des-threoninol-octreotide is a potent somatostatin receptor inhibitor, primarily targeting the mSSTR2b, rSSTR5, and hSSTR5 receptor subtypes. This compound demonstrates high inhibitory activity with IC50 values of 13.62 nM, 10.63 nM, and 10.95 nM, respectively. It is valuable for research applications exploring neuroendocrine regulation, peptide hormone signaling, and potential therapeutic interventions involving somatostatin pathways. -
Somatostatin Agonist
Pasireotide (diaspartate) is a long-acting somatostatin agonist targeting somatostatin receptors sst1, sst2, sst3, sst4, and sst5, with pKi values of 8.2, 9.0, 9.1, <7.0, and 9.9, respectively. This cyclohexapeptide compound demonstrates significant antisecretory, antiproliferative, and proapoptotic activities. Its diverse biological effects make it a valuable tool for research applications in endocrinology and oncology, particularly in the study of neuroendocrine tumors and hormonal regulation. -
Somatostatin Analogue
Nendratareotide is a somatostatin analogue that primarily targets somatostatin receptors. It exhibits inhibitory effects on hormone secretion, making it valuable in the treatment of neuroendocrine tumors and acromegaly. This compound is also utilized in research focused on understanding the physiological roles of somatostatin and its impact on glucose metabolism and cell proliferation. -
Neuropeptide
Cortistatin-29 is a rat neuropeptide that targets somatostatin receptors (SSTRs) with high affinity, exhibiting IC50 values of 2.8 nM for SSTR1, 7.1 nM for SSTR2, 0.2 nM for SSTR3, 3.0 nM for SSTR4, and 13.7 nM for SSTR5. This compound is known to alleviate neuropathic pain and demonstrates anti-fibrotic properties. Its diverse biological activities make it a valuable tool for research in neurobiology and fibrosis-related studies. -
SSTR5 Antagonist
SSTR5 antagonist 6 is a selective antagonist for somatostatin receptor subtype 5 (SSTR5), exhibiting an IC50 of 24 nM. This compound plays a significant role in modulating signaling pathways associated with glucose homeostasis and insulin regulation, making it valuable for research related to type 2 diabetes. Its oral bioactivity enhances its potential for in vivo studies, facilitating exploration of SSTR5's impact on metabolic disorders. -
SST1 Antagonist
SST1 receptor antagonist-1 is a selective antagonist of the Somatostatin receptor 1 (SST1), exhibiting pKds of 9.11 and 8.79 for rat and human SST1, respectively. This compound is utilized in research focused on retinal and endocrine dysfunctions, as well as cancer and neuropsychiatric disorders, making it a valuable tool for investigating the role of SST1 in various biological systems. -
sstr3 Antagonist
MK-1421 is a potent and selective antagonist of the somatostatin receptor type 3 (sstr3). By inhibiting sstr3, MK-1421 plays a significant role in the modulation of insulin secretion, making it a valuable tool in research related to type 2 diabetes. Its specificity and efficacy make it suitable for investigating the complex pathways involved in metabolic disorders. -
Somatostatin Analogue
[D-Trp8,Tyr11] Somatostatin is a somatostatin analogue that enhances the hormone's stability and bioactivity. This compound is known to inhibit the secretion of growth hormone and other hormones, making it valuable in studies related to hormonal regulation and physiological processes. Applications include endocrynology research and the investigation of tumor growth inhibition, particularly in neuroendocrine tumors. -
Somatostatin-28 (1-14) Analogue
[Tyr12] Somatostatin 28 (1-14) is an analogue of Somatostatin-28 (1-14) that targets somatostatin receptors to modulate neuropeptide signaling. This peptide fragment plays a crucial role in the regulation of various physiological processes, including hormone secretion and cell proliferation. It is commonly used in research applications focused on neuroendocrine signaling pathways and therapeutic interventions for endocrine-related disorders. -
SSTR4 Agonist
SSTR4 Agonist 3 is a selective agonist for the somatostatin receptor subtype 4 (SSTR4), which is primarily expressed in the hippocampus and neocortex, areas implicated in memory and learning. This compound demonstrates significant biological activity in rodent models, exhibiting anti-nociceptive and anti-inflammatory effects that are relevant to both acute and chronic pain conditions. SSTR4 Agonist 3 holds potential for further research into pain modulation and Alzheimer's disease pathology. -
Tetradecapeptide
[D-Trp8] Somatostatin-14 is a tetradecapeptide analog of somatostatin that exhibits enhanced potency compared to its native counterpart. This compound primarily targets somatostatin receptors, influencing various physiological processes including hormonal secretion and cell proliferation. It is utilized in research applications focusing on neuroendocrine regulation and the therapeutic potential of somatostatin analogs in treating conditions such as acromegaly and neuroendocrine tumors. -
Dimer Parallel
Octreotide dimer (parallel) is a parallel dimer of Octreotide, a synthetic octapeptide that acts as an agonist of somatostatin receptors. This compound exhibits potent inhibitory effects on hormone secretion, making it valuable for research in neuroendocrine tumors and diagnostic imaging. Octreotide dimer (parallel) is employed in studies exploring endocrine regulation and potential therapeutic applications in various somatostatin receptor-related disorders. -
Somatostatin Analog
AP102 is a dual somatostatin receptor analogue targeting SSTR2 and SSTR5. This disulfide-bridged octapeptide exhibits subnanomolar affinity for SSTR2 and SSTR5, with IC50 values of 0.63 nM and 0.65 nM, respectively, while showing no binding to SSTR1 or SSTR3. AP102 is particularly valuable in research related to acromegaly and neuroendocrine tumors, providing insights into receptor-specific signaling pathways. -
sst2 Agonist
(1R,1'S,3'R/1R,1'R,3'S)-L-054,264 is a selective non-peptide agonist for the human somatostatin receptor subtype 2 (sst2). This compound is instrumental in investigating the role of sst2 in retinal neuromodulation, making it valuable for research on neurobiology and related therapeutic applications. Its unique selectivity allows for precise modulation of receptor activity, facilitating studies on somatostatin-mediated pathways. -
sst4 Receptor Agonist
L-803087 TFA is a potent and selective agonist of the somatostatin sst4 receptor, exhibiting a Ki value of 0.7 nM. Demonstrating over 280-fold selectivity for the sst4 receptor compared to other somatostatin receptors, L-803087 TFA enhances AMPA-mediated synaptic responses in the hippocampus. This compound is also noted for its role in increasing kainate-induced seizures in murine models, making it valuable for research into neurophysiological processes and receptor signaling mechanisms. -
SST1 Antagonist
SST1 receptor antagonist-2 is a piperazine derivative that selectively inhibits somatostatin receptor 1 (SST1). This compound displays significant potential in the investigation of psychiatric disorders, neurodegenerative diseases, tumors, vascular conditions, and immunological diseases. Its selective antagonism of SST1 may provide insights into various pathological processes and therapeutic strategies. -
SSTR2 Agonist
Branosotine is a potent agonist of the somatostatin receptor subtype 2 (SSTR2), exhibiting an EC50 of less than 0.1 nM. This compound demonstrates significant biological activity in modulating neuroendocrine signaling pathways, making it a valuable tool for research involving neuropsychiatric disorders and hormonal regulation. Its high specificity and efficacy position Branosotine as an important reagent for studying SSTR2-related biological processes. -
Somatostatin Receptor Agonist
Zavolosotine is an orally active agonist of the somatostatin receptor type 5 (SST5), exhibiting a potent EC50 of less than 1 nM. This compound effectively inhibits insulin and glucagon secretion while also elevating glucagon levels in a rat model. Zavolosotine is valuable for research in glucose metabolism and endocrine signaling pathways, making it a key reagent for studies on metabolic disorders and diabetes. -
SSTR4 Agonist
Mazisotine tartrate is a potent SSTR4 agonist that selectively activates the somatostatin receptor subtype 4. This compound is primarily involved in modulating neuroendocrine functions and has potential applications in the study of metabolic disorders, neuroprotection, and cancer therapy. Its biological activity suggests utility in investigating signaling pathways linked to this receptor subtype, making it a valuable tool for research in endocrinology and related fields. -
SSTR5 Antagonist
SSTR5 Antagonist 3 is a potent inhibitor targeting the somatostatin receptor subtype 5 (SSTR5) with IC50 values of 2.8 nM in human tissues and 1.4 nM in mouse models. This orally bioavailable compound exhibits low hERG inhibition, making it suitable for in vivo studies. SSTR5 Antagonist 3 is primarily utilized in research focusing on anti-gallstone therapies and the modulation of related gastrointestinal functions. -
Urotensin II Anague
Urotensin II-related peptide is an analog of human urotensin II, exhibiting high affinity for the urotensin II receptor (UT). This peptide plays a significant role in cardiovascular regulation and may influence vascular smooth muscle contraction. It is commonly utilized in research focused on cardiovascular diseases, neurobiology, and the study of peptide receptor interactions. -
Urotensin Receptor Antagonist
SB-611812 is a selective antagonist of the urotensin II receptor (UTR), which plays a significant role in cardiovascular regulation. This compound is useful in investigating the pathological mechanisms underlying cardiovascular diseases and may aid in the development of novel therapeutic strategies targeting UTR-mediated pathways. Researchers can utilize SB-611812 to explore its effects on vascular function and cardiac remodeling in experimental models. -
Urotensin II Receptor Antagonist
SB-706375 is an antagonist of the Urotensin II (UII) receptor, which plays a key role in renal physiology. By inhibiting this receptor, SB-706375 effectively decreases the kidney's response to UII and Urotensin-related peptide (URP), leading to a significant increase in Glomerular Filtration Rate (GFR). This compound is valuable for research applications focused on kidney diseases and hypertension, facilitating further understanding of renal function and associated pathologies. -
Urotensin-II Receptor Antagonist
GSK 1562590 hydrochloride is a potent and selective antagonist of the urotensin-II receptor (UT), exhibiting pKi values ranging from 9.14 to 9.66 across various mammalian species, including mouse, rat, cat, monkey, and human. This compound demonstrates significant inhibition of UT-mediated signaling pathways, making it valuable for research into cardiovascular and neuroendocrine disorders associated with urotensin-II. Its high affinity and selectivity position GSK 1562590 as an essential tool for studying the role of urotensin-II in physiological and pathological processes. -
urotensin-II Receptor Antagonist Peptide
Urantide is a selective and competitive antagonist of the urotensin-II (UT) receptor, exhibiting a pKB of 8.3. This peptide effectively inhibits human urotensin-II (hU-II)-induced contractions in rat thoracic aorta ex vivo. Urantide is valuable for investigating the (patho)physiological roles of hU-II in the mammalian cardiovascular system, making it an important tool for related research applications. -
Urotensin Receptor Agonist
Urotensin II (114-124), human, is a peptide comprising 11 amino acids that functions as a potent vasoconstrictor and an agonist for the urotensin receptor (GPR14). This compound is utilized in research to explore cardiovascular function and pathophysiology, particularly regarding its role in regulating vascular tone and blood pressure. Its biological activity makes it a valuable tool for studying urotensin signaling pathways and their implications in various disease states. -
Urotensin II Antagonist
Palosuran hydrochloride is a selective, orally active antagonist of the urotensin II receptor, exhibiting an IC50 of 3.6 nM in CHO cell membranes expressing human recombinant receptors. This compound demonstrates potential to improve pancreatic and renal function in diabetic models, making it a valuable tool for research in metabolic and renal disorders. Its mechanism and target highlight its relevance in studies of urotensin II signaling pathways. -
Urotensin Receptor Agonist
AC-7954 free base is a selective nonpeptidic agonist of the urotensin receptor, demonstrating an EC50 of 300 nM at the human urotensin II receptor. This compound is valuable for research focused on the urotensin signaling pathway and its implications in cardiovascular and metabolic disorders. Its specificity makes it suitable for studies investigating the physiological and pathological roles of urotensin receptors in various biological systems. -
Urotensin Receptor Agonist
AC-7954 is a selective nonpeptidic agonist of the urotensin receptor, exhibiting an EC50 of 300 nM at the human urotensin II receptor. This compound plays a significant role in cardiovascular and metabolic research, with potential applications in the study of hypertension and heart failure. AC-7954 can be utilized to explore urotensin-related signaling pathways and their implications in various physiological processes. -
Urotensin Receptor Antagonist
SB-436811 is a selective antagonist of the urotensin-II receptor, exhibiting a pKi value of 6.7. This compound is primarily utilized in research focused on cardiovascular and metabolic disorders, where the urotensin-II pathway plays a significant role. By inhibiting urotensin-II activity, SB-436811 can aid in the exploration of its physiological effects and potential therapeutic applications. -
Endothelin A Receptor Antagonist
JKC 301 is a selective Endothelin A receptor antagonist that effectively mitigates the pressor effects of nicotine in rat models. This compound is particularly valuable for investigating the cardiovascular diseases associated with smoking. Its targeted mechanism makes JKC 301 a useful tool for researchers studying the pathophysiological effects of nicotine on cardiovascular function. -
Precursor of Endothelin-1
Big Endothelin-1 (1-39), porcine is the precursor peptide of endothelin-1 (ET-1), a potent vasoconstrictor significantly involved in cardiovascular regulation. This reagent exhibits similar pressor effects in vivo, making it valuable for studies investigating vascular function and regulation. It is useful in research applications that aim to elucidate the roles of endothelin peptides in physiological and pathological processes. -
platelet aggregation inhibitor
Trifenagrel is an orally active platelet aggregation inhibitor that targets the pathways induced by arachidonic acid and collagen. It demonstrates significant biological activity, with ED50 values of 1.4 mg/kg and 9.4 mg/kg for the inhibition of AA- and collagen-induced platelet aggregation in guinea pigs, respectively. This compound serves as a valuable tool in cardiovascular research and the study of thrombotic disorders. -
Platelet-activating Factor Receptor (PAFR) Inhibitor
TSI-01 is a selective inhibitor of the Platelet-activating Factor Receptor (PAFR), targeting lysophosphatidylcholine acyltransferase (LPCAT)2. This compound exhibits a potent inhibitory effect with an IC50 of 0.47 μM for human LPCAT2, significantly more effective than its activity on LPCAT1 (IC50 = 3.02 μM). TSI-01 effectively suppresses PAF biosynthesis in mouse peritoneal macrophages when stimulated with a calcium ionophore at a concentration of 60 μM. This makes TSI-01 a valuable tool for investigating inflammatory processes and related conditions in research applications. -
PAFR Antagonist
MK 287 is a potent and selective antagonist of the platelet-activating factor receptor (PAFR). It effectively inhibits [3H]C18-PAF binding to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes, with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 also demonstrates the ability to inhibit PAF-induced platelet aggregation and elastase release from PMNs, with ED50 values of 56, 1.5, and 4.4 nM. This compound is valuable for research focused on cardiovascular diseases, including thrombosis.
